,43 The placebo-controlled DAPA-CKD trial evaluated the effects of the SGLT2 inhibitor, dapagliflozin on renal and cardiovascular outcomes in adults with diabetic and nondiabetic CKD, including 104 patients with biopsy-confirmed FSGS.42 The gene discussed is SLC5A2; the disease is focal segmental glomerulosclerosis.